Shopping Cart 0
Cart Subtotal
USD 0

Gonorrhea-Pipeline Review, H1 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Gonorrhea-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gonorrhea-Pipeline Review, H1 2017, provides an overview of the Gonorrhea (Infectious Disease) pipeline landscape.

Gonorrhea is an infection caused by a sexually transmitted bacterium that can infect both males and females. Gonorrhea most often affects the urethra, rectum or throat. In females, gonorrhea can also infect the cervix. Symptoms include painful urination, pus-like discharge from the tip of the penis, increased vaginal discharge, painful urination, abdominal pain and pelvic pain. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gonorrhea-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Gonorrhea (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gonorrhea (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Gonorrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 2 and 1 respectively.

Gonorrhea (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Gonorrhea (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Gonorrhea (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Gonorrhea (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Gonorrhea (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Gonorrhea (Infectious Disease)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Gonorrhea (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Gonorrhea (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Gonorrhea-Overview

Gonorrhea-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Gonorrhea-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gonorrhea-Companies Involved in Therapeutics Development

Debiopharm International SA

Entasis Therapeutics Inc

Merck & Co Inc

Recce Ltd

Gonorrhea-Drug Profiles

Debio-1453-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

edodekin alfa SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target Bacterial Cell Wall for Gonorrhoea and Tuberculosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zoliflodacin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gonorrhea-Dormant Projects

Gonorrhea-Discontinued Products

Gonorrhea-Product Development Milestones

Featured News & Press Releases

Oct 28, 2016: Entasis Therapeutics to Present Data on ETX0914 at IDWeek 2016

Sep 21, 2016: Entasis Announces Positive Phase 2 Data of ETX0914 for the Treatment of Gonorrhea

Dec 22, 2015: Cempra Enters Into a CRADA With the NIAID and Expands the Phase 3 Solithromycin Clinical Trial in Urogenital Gonorrhea to Include Additional Female Patients and Adolescents

Nov 19, 2014: Cempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies

Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection

Apr 26, 2013: Cempra To Present Data On Solithromycin's Potential Against Urogenital Infections And Multidrug-Resistant Pathogens At ECCMID

Oct 04, 2012: Cempra Announces Positive Top-Line Results From Solithromycin Phase II Clinical Trial In Patients With Uncomplicated Urogenital Gonorrhea

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Gonorrhea, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Gonorrhea, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Gonorrhea-Pipeline by Debiopharm International SA, H1 2017

Gonorrhea-Pipeline by Entasis Therapeutics Inc, H1 2017

Gonorrhea-Pipeline by Merck & Co Inc, H1 2017

Gonorrhea-Pipeline by Recce Ltd, H1 2017

Gonorrhea-Dormant Projects, H1 2017

Gonorrhea-Discontinued Products, H1 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Gonorrhea Therapeutic Products under Development, Key Players in Gonorrhea Therapeutics, Gonorrhea Pipeline Overview, Gonorrhea Pipeline, Gonorrhea Pipeline Assessment


Companies

Debiopharm International SA, Entasis Therapeutics Inc, Merck & Co Inc, Recce Ltd